Ennovation Ventures Portfolio | The global multicenter registered phase III clinical trial of TransThera's core product, Tegotinib monotherapy, for the treatment of advanced cholangiocarcinoma patients has been completed and enrolled
Nanjing, China, and Gaithersburg, Maryland, USA | July 2, 2026 –TransTheraSciences(Nanjing),Inc ( "TransThera